drugset / Trial / NCT02638545

Hemodynamic Effects of Dexmedetomidine in Septic Shock

NCT02638545

Phase 3 Completed 37 enrolled University of Roma La Sapienza
NaSingle-groupOpen-labelTreatment

Summary

The current treatment regimen of patients with septic shock requires a sufficient hemodynamic support aiming to preserve tissue oxygen requirements and perfusion. Therefore, aggressive fluid challenge and vasopressor agents play a pivotal role. To increase total peripheral resistance and preserve organ perfusion, a continuous infusion of catecholamines is often needed. Because sepsis is usually associated with adrenergic receptor and post-receptor abnormalities, the efficacy of such treatment regimens often gradually decreases over time, thereby complicating hemodynamic support. Experimental evidence suggest that α-2 agonists increase pressor responsiveness following lipopolysaccharide administration. This study will assess the effects of the sedation with dexmedetomidine (α-2 agonist) on norepinephrine requirements in patients with septic shock.

Timeline

Start
2015-09
Primary completion
2017-01
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified